| 4 | Loss from operations |
| 2017 | 2016 | 2015 | ||||||||||
| Loss
from operations is stated after charging/(crediting): |
£’000 | £’000 |
|
£'000
|
||||||||
| Changes
in inventories of finished goods and work in progress |
202 | 256 | 62 | |||||||||
| Write down of inventory to net realisable value | - | 287 | - | |||||||||
| Depreciation of property, plant and equipment | 983 | 772 | 501 | |||||||||
| Amortisation
of intangible assets – product and marketing rights |
1,577 | 3,583 | 236 | |||||||||
| Impairment of intangible assets | 1,500 | 11,413 | - | |||||||||
| Operating lease expense: | ||||||||||||
| - Property | 277 | 385 | 246 | |||||||||
| - Plant and machinery | - | 194 | 86 | |||||||||
| Foreign exchange(gain)/ loss | (39 | ) | 31 | (23 | ) | |||||||
| Acquisition costs | - | - | 2,991 | |||||||||
| Loss on disposal of property, plant and equipment | 27 | - | 2,553 | |||||||||
| Gain on bargain purchase | - | - | (165 | ) | ||||||||
| Share based payment | 520 | 203 | 170 | |||||||||
Acquisition costs relate to professional fees incurred on the acquisition of Midatech Pharma US, Inc. and Zuplenz® in 2015 and Midatech Pharma (Wales) Limited in 2014.
Amortisation of product and marketing rights are included with distribution costs, sales and marketing expenses.